Compare SMTI & HPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMTI | HPF |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.2M | 278.9M |
| IPO Year | 2008 | 2002 |
| Metric | SMTI | HPF |
|---|---|---|
| Price | $32.21 | $13.25 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 113.7K | 90.8K |
| Earning Date | 11-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $14.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $12.67 |
| 52 Week High | $35.52 | $16.83 |
| Indicator | SMTI | HPF |
|---|---|---|
| Relative Strength Index (RSI) | 35.41 | 51.18 |
| Support Level | $30.40 | $12.67 |
| Resistance Level | $34.36 | $16.00 |
| Average True Range (ATR) | 0.95 | 0.17 |
| MACD | -0.09 | 0.09 |
| Stochastic Oscillator | 68.77 | 97.92 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
John Hancock Preferred Income Fund II is a United States based closed-end, diversified management investment company. Its primary objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, capital preferred securities and short-term investments.